A Review of Economic Evaluations of Darunavir Boosted by Low-Dose Ritonavir in Treatment-Experienced Persons Living with HIV Infection
- First Online:
Darunavir boosted by low-dose ritonavir (DRV/r), at a daily dose of 600/100mg twice a day (bid), has been shown to be superior to alternative highly active antiretroviral therapy (HAART) regimens for the management of treatment-experienced, HIV-infected adults in the phase IIb POWER trials and the phase III TITAN trial.
Economic analyses of different types that have been performed for several countries to investigate the cost effectiveness and budgetary impact of DRV/r 600/100mg bid for treatment-experienced people living with HIV (PLHIV) based on the clinical data gathered in the POWER and TITAN trials are reviewed for consistency and their value to different decision-makers is assessed.
Cost-utility analyses for the USA and several European countries indicate that DRV/r-based HAART is cost effective compared with other standard of care protease inhibitor (PI)-based regimens in PLHIV with evidence of PI resistance. For all of these countries, the estimated cost-utility ratio is well below typical benchmark values and these ratios are robust, as demonstrated by one-way sensitivity and variability analyses and multi-way probabilistic sensitivity analyses.
Studies using other metrics including the average 1-year drug cost per patient with a plasma HIV-RNA level less than 50 copies/mL at 48 weeks, the incremental drug cost per additional patient with a plasma HIV-RNA level less than 50 copies/mL at 48 weeks, the total (antiretroviral and nonantiretroviral) costs during the first year of treatment, and the total healthcare budget impact during the first 5 years of treatment provided further evidence of the positive economic outcomes with the use ofDRV/r in treatmentexperienced PLHIV.
Different measures of economic outcomes are useful for different types of decision-makers and different types of decisions. In general, the results of these different types of analyses will be consistent with each other. For darunavir, the economic analyses reviewed in this paper demonstrate that the use of DRV/r 600/100mg bid in the management of HIV-infected, treatmentexperienced adults who have failed at least one of the other currently available PIs is cost effective and may be cost saving.
- 1.US Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents (USDHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; 2008 Jan 29 [online]. Available from URL: (http://AIDSinfo.nih.gov) [Accessed 2009 Dec 10]Google Scholar
- 11.Simpson KN, Chumney ECG, Hicks CB, et al. Cost effectiveness of tipranavir in treatment-experienced HIV patients in the USA [poster PIN10]. 11th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2006 May 20–24; Philadelphia, Pennsylvania, USAGoogle Scholar
- 17.Pozniak A, Jayaweera D, Hoy J, et al. Efficacy of darunavir/ritonavir in treatment-experienced HIV-1-infected patients at 96 weeks in the POWER 1 and 2 trials [abstract P7.2/0]. 11th European AIDS Conference; 2007 October 2427; Madrid, SpainGoogle Scholar
- 20.Katlama C, Bellos N, Grinsztejn B, et al. POWER 1 and 2: combined final 144-week efficacy and safety results for darunavir/ritonavir 600/100mg bid in treatment-experienced HIV patients [abstract]. 9th International Congress on Drug Therapy in HIV Infection; 2008 Nov 913; Glasgow, UKGoogle Scholar
- 22.Pozniak A, Arasteh K, Molina JM, et al. POWER 3 analysis: 144-week efficacy and safety results for darunavir/ritonavir 600/100 mg bid in treatment-experienced patients [abstract]. 9th International Congress on Drug Therapy in HIV Infection; 2008 Nov 913; Glasgow, UKGoogle Scholar
- 23.Arastéh K, Grinsztejn B, de Béthune MP, et al. Efficacy analysis of darunavir/r in treatment-experienced POWER 3 patients at Week 96 [abstract P7.2/05]. 11th European AIDS Conference; 2007 Oct 2427; Madrid, SpainGoogle Scholar
- 24.Banhegyi D, Katlama C, da Cunha C, et al. Phase III TITAN week 96 final analysis: efficacy/safety of darunavir/r (DRV/r) vs. lopinavir/r (LPV/r) in LPV-naïve, treatment experienced patients [abstract]. 9th International Congress on Drug Therapy in HIV Infection; 2008 Nov 913, Glasgow, UKGoogle Scholar
- 26.Moeremans K, Hemmett L, Hjelmgren J, et al. Cost effectiveness of darunavir/ritonavir 600/100mg bid in treatmentexperienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK. PharmacoEconomics 2010; 28 Suppl. 1: 147–67PubMedCrossRefGoogle Scholar
- 28.Canadian Agency for Drugs and Technologies in Health (CADTH). CADTH guidelines for the evaluation of health technologies: Canada, 3rd ed. 2006. Available at: (http://www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf) [Accessed 2010 Jun 30]
- 29.National Institute for Health and Clinical Excellence (NICE). Single technology appraisal specification for manufacturer/sponsor submission of evidence. 2009. Available at: (http://www.nice.org.uk/media/E29/DF/SpecificationForManufacturerSponsorSubmissionofEvidenceDraft.pdf) [Accessed 2010 Jun 30]Google Scholar
- 30.Pharmaceutical Benefits Advisory Committee (PBAC). Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee, version 4.2. 2007. Available at: (http://www.health.gov.au/internet/main/publishing.nsf/Content/pbacguidelines-index) [Accessed 2010 Jun 30]Google Scholar
- 31.National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal; 2008 June [online]. Available from URL: (http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf) [Accessed 2009 Dec 10]Google Scholar
- 33.Towse A. What is NICE’s threshold? An external view. Chapter 2. In: Devlin N, Towse A, editors. Cost effectiveness thresholds: economic and ethical issues. London: King’s Fund/Office for Health Economics, 2002Google Scholar
- 37.European AIDS Clinical Society (EACS). 2009 Guidelines for the clinical management and treatment of HIVinfected adults in Europe; [online]. Available from URL: (http://www.europeanaidsclinicalsociety.org/guidelinespdf/EACS-EuroGuidelines2009FullVersion.pdf) [Accessed 2009 Dec 10]
- 44.IQWiG (Instutut für Qualität und Wirtschaftlichkeit im Gesundheitswesen-Institute for Quality and Efficiency in Health Care). Methods for assessment of the relation of benefits to costs in the German statutory health care system. Version 1, 24th January, 2008Google Scholar
- 45.Annemans L, Hill A, Smets E, et al. Cost-effectiveness of current treatment options in treatment-resistant HIV/AIDS patients in the German setting [abstract PE19.5/5]. 12th European AIDS Conference; 2009 Nov 1114, Cologne, GermanyGoogle Scholar
- 46.Brogan A, Soorapanth S, Donatz V, et al. Comparative costefficacy analysis of darunavir/r and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in Germany [abstract PIN48]. 12th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2009 October 2427; Paris, FranceGoogle Scholar
- 48.Smets E, Stoll M, Hill A, et al. Comparative cost-efficacy analysis of darunavir/r and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in Germany [abstract PE19.5/3]. 12th European AIDS Conference; 2009 Nov 1114, Cologne, GermanyGoogle Scholar
- 52.Holkmann Olsen C, Gatell J, Ledergerber B, et al. Risk of AIDS and death at given HIV-RNA and CD4 cell counts, in relation to specific antiretroviral drugs in the regimen. AIDS 2005; 19: 319–30Google Scholar
- 53.Weber R, Friis-Moller N, Sabin C, et al. HIV and non-HIVrelated deaths and their relationship to immunodeficiency: the D:A:D study [abstract 595]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 2225; Boston, MA, USAGoogle Scholar
- 55.Health Protection Agency (HPA) Center for Infections. A complex picture. HIV and other sexually transmitted infections in the United Kingdom; 2006 [online]. Available from URL: (http://www.hpa.org.uk/publications/2006/hiv_sti_2006/default.htm) [Accessed 2009 Dec 10]Google Scholar
- 62.DeJesus E, Ortiz R, Khanlou H, et al. Efficacy and safety of darunavir/ritonavir versus lopinavir/ritonavir in ARV treatment-nai ve HIV-1-infected patients at week 48: ARTEMIS [abstract H-718b]. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sept 1720; Chicago, IL, USAGoogle Scholar
- 63.Berger DS, Northland R, Scribner A, et al. Effect of baseline factors on virological response to darunavir/r and lopinavir/r at week 48 in TITAN [abstract P7.3/27]. 11th European AIDS Conference; 2007 Oct 2427; Madrid, SpainGoogle Scholar
- 65.Maggiolo F, Ripamonti D, Gregis G, et al. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-nai ve, HIV-1-infected patients. Antiviral Ther 2003; 8: 339–46Google Scholar